← Back to Search

MDS patients for Myelodysplastic Syndrome

N/A
Waitlist Available
Led By Rashmi S Goswani, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This study evaluates the relationship between myelodysplastic syndromes (MDS) and cardiovascular disease. MDS patients will be evaluated for the presence of mutations and whether they are associated with an increased risk of heart disease (CVD) and inflammation compared to healthy adults. Patients without symptoms of CVD will receive CT scans to assess for hidden disease and if that is related to their mutations.

Eligible Conditions
  • Myelodysplastic Syndrome
  • Cardiovascular Disease
  • Inflammation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Identify any correlation between selected myeloid mutations and/or their VAF with the presence of pre-existing incident or occult CAD
Measure the allelic frequency and type of myeloid cancer-associated mutations in MDS patients diagnostic bone marrow aspirates or slides
Screen for occult and potentially clinically significant CAD in MDS patients by means of coronary CT
Secondary outcome measures
Screen for serum inflammatory cytokines in the blood of patients with incident or occult CAD
Track how often newly discovered CAD from coronary CT leads to further intervention or changes in monitoring

Trial Design

1Treatment groups
Experimental Treatment
Group I: MDS patientsExperimental Treatment3 Interventions
All Canadian MDS patients on the MDS-database to be included.

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
656 Previous Clinical Trials
1,551,037 Total Patients Enrolled
Ontario Molecular Pathology Research NetworkUNKNOWN
Queen's UniversityOTHER
365 Previous Clinical Trials
120,017 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia
2019. "Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04110925.
All > Cardiovascular
~72 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top